Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: A prospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 5, 2004, Pages 921-931

  Resino, Salvador ^a   Bellón, José Ma ^a   Ramos, José Tomás ^b   Gonzalez Rivera, Milagros ^a   de José, Ma Isabel ^c   González, Ma Isabel ^b   Gurbindo, Dolores ^a   Mellado, Ma José ^c   Cabrero, Esther ^d   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d ABBOTT LABORATORIES   (Spain)

Author keywords

CD4+ T lymphocytes; HAART; Viral load

Indexed keywords

AMPRENAVIR; CHOLESTEROL; EFAVIRENZ; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AGE; ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PROSPECTIVE STUDY; REBOUND; SALVAGE THERAPY; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY;

EID: 8844280062     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh431     Document Type: Article

References (57)

1. Shearer, W. T., Quinn, T. C., LaRussa, P. et al. (1997). Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. New England Journal of Medicine 336, 1337-42.
2. Borkowsky, W., Stanley, K., Douglas, S. D. et al. (2000). Immunological response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. Journal of Infectious Diseases 182, 96-103.
3. Wintergerst, U., Hoffmann, F., Solder, B. et al. (1998). Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatric Infectious Disease Journal 17 517-8.
4. Mueller, B. U., Nelson, R. P., Jr, Sleasman, J. et al. (1998). A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Journal of Infectious Diseases 177, 557-64.
5. Wiznia, A., Stanley, K., Krogstad, P. et al. (2000). Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. Paediatric AIDS Clinical Trials Group 377 Study Team. AIDS Research and Human Retroviruses 16 1113-21.
6. Rutstein, R. M., Feingold, A., Meislich, D. et al. (1997). Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 11, F107-11.
7. Resino, S., Bellón, J., Resino, R. et al. (2004). Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clinical Infectious Diseases 38, 1605-12.
8. Resino, S., Bellón, J., Gurbindo, D. et al. (2003). Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clinical Infectious Diseases 37, 1216-25.
9. Nachman, S. A., Stanley, K., Yogev, R. et al. (2000). Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Paediatric AIDS Clinical Trials Group 338 Study Team. Journal of the American Medical Association 283, 492-8.
10. Starr, S. E., Fletcher, C. V., Spector, S. A. et al. (1999). Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Paediatric AIDS Clinical Trials Group 382 Team. New England Journal of Medicine 341, 1874-81.
11. Starr, S. E., Fletcher, C. V., Spector, S. A. et al. (2002). Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 21 659-63.
12. Hirsch, M. S., Conway, B., D'Aquila, R. T. et al. (1998). Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. Journal of the American Medical Association 279, 1984-91.
13. Aleman, S., Soderbarg, K., Visco-Comandini, U. et al. (2002). Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16, 1039-44.
14. Murphy, R. L., Brun, S., Hicks, C. et al. (2001). ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15, F1-9.
15. Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2002). Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 7, 165-74.
16. Saez-Llorens, X., Violari, A., Deetz, C. O. et al. (2003). Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 22, 216-24.
17. Condra, J. H., Schleif, W. A., Blahy, O. M. et al. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Science 268, 35.
18. Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2001). Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 75, 7462-9.
19. Munoz-Fernandez, M. A., Obregon, E., Navarro, J. et al. (1996). Relationship of virological, immunological, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatric Research 40, 597-602.
20. Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T. et al. (2000). Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. Journal of the American Medical Association 283, 2417-26.
21. Centers for Disease Control and Prevention (1998). Guidelines for use of antiretroviral agents in paediatric HIV infection. Morbidity and Mortality Weekly Report 47, 1-43.
22. Centers for Disease Control and Prevention (1994). Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbidity and Mortality Weekly Report 43, 1-10.
23. Sharland, M., di Zub, G. C., Ramos, J. T. et al. (2002). PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Paediatric European Network for Treatment of AIDS. HIV Medicine 3, 215-26.
24. Lucas, G. M., Chaisson, R. E. & Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virological failure and adverse drug reactions. Annals of Internal Medicine 131, 81-7.
25. Mocroft, A., Phillips, A. N., Miller, V. et al. (2001). The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 15, 201-9.
26. Mocroft, A., Devereux, H., Kinloch-de-Loes, S. et al. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 14, 1545-52.
27. Romano, L., Peduzzi, C., Venturi, G. et al. (2002). Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice. Journal of Acquired Immune Deficiency Syndromes 30, 533-5.
28. Melvin, A. J., Mohan, K. M., Arcuino, L. A. et al. (1997). Clinical, virological and immunological responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Clinical and Experimental Immunology 110 15-21.
29. van Rossum, A. M., Niesters, H. G., Geelen, S. P. et al. (2000). Clinical and virological response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicentre study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections. Journal of Pediatrics 136, 780-8.
30. Deeks, S. G., Barbour, J. D., Grant, R. M. et al. (2002). Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viraemia. AIDS 16, 201-7.
31. Resino, S., Bellón, J. M., Gurbindo, D. et al. (2002). Dynamics of progression markers in a non-study population of HIV-1 vertically infected infants with different antiretroviral treatments. Acta Paediatrica 91, 776-82.
32. Resino, S., Correa, R., Bellon, J. et al. (2002). Characterizing immune reconstitution after long-term HAART in paediatric AIDS. AIDS Research and Human Retroviruses 18, 1395-406.
33. Resino, S., Sanchez-Ramon, S., Bellon, J. M. et al. (2002). Immunological recovery after 3 years' antiretroviral therapy in HIV-1-infected children. AIDS 16, 483-6.
34. Mocroft, A., Gill, M. J., Davidson, W. et al. (1998). Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 12, 2161-7.
35. Fatkenheuer, G., Theisen, A., Rockstroh, J. et al. (1997). Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11, F113-6.
36. Nadal, D., Steiner, F., Cheseaux, J. J. et al. (2000). Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Paediatric AIDS Group of Switzerland. Infection 28, 287-96.
37. Resino, S., Bellón, J., Gurbindo, D. et al. (2004). CD38 in CD8+ T cells predict virological failure in HIV-infected children receiving antiretroviral therapy. Clinical Infectious Diseases 38, 412-7.
38. Melvin, A. J., Rodrigo, A. G., Mohan, K. M. et al. (1999). HIV-1 dynamics in children. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20, 468-73.
39. Purswani, M., Johann-Liang, R., Cervia, J. et al. (1999). Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Lancet 353, 2240.
40. Staszewski, S., Miller, V., Sabin, C. et al. (1999). Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 13, 367-73.
41. Gilleece, Y. C., Qazi, N. A., Morlese, J. F. et al. (2003). The efficacy of lopinavir in individuals experiencing protease inhibitor failure. Journal of Acquired Immune Deficiency Syndromes 32, 238-40.
42. Fatkenheuer, G., Romer, K., Kamps, R. et al. (2001). Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS 15 2334-5.
43. Mauss, S., Schmutz, G. & Kuschak, D. (2002). Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 16, 296-7.
44. Bratt, G., Karlsson, A., Leandersson, A. C. et al. (1998). Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 12, 2193-202.
45. Le Moing, V., Chene, G., Carrieri, M. P. et al. (2002). Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16, 21-9.
46. Mellors, J. W., Munoz, A., Giorgi, J. V. et al. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126, 946-54.
47. Bongiovanni, M., Bini, T., Adorni, F. et al. (2003). Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antiviral Therapy 8, 209-14.
48. Monno, L., Saracino, A., Scudeller, L. et al. (2003). HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. Journal of Acquired Immune Deficiency Syndromes 33, 439-47.
49. Prado, J. G., Wrin, T., Beauchaine, J. et al. (2002). Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16, 1009-17.
50. Tsuchiya, K., Matsuoka, S., Hachiya, A. et al. (2001). Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. AIDS 15, 1183-4.
51. Cooper, C. L., Parbhakar, M. A. & Angel, J. B. (2002). Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clinical Infectious Diseases 34, 1259-63.
52. Clumeck, N., Goebel, F., Rozenbaum, W. et al. (2001). Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15, 1517-26.
53. Hurst, M. & Faulds, D. (2000). Lopinavir. Drugs 60 1371-81.
54. Gutierrez, F., Padilla, S., Navarro, A. et al. (2003). Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. Journal of Acquired Immune Deficiency Syndromes 33, 594-600.
55. Havlir, D. V., Bassett, R., Levitan, D. et al. (2001). Prevalence and predictive value of intermittent viremia with combination HIV therapy. Journal of the American Medical Association 286, 171-9.
56. Havlir, D. V., Marschner, I. C., Hirsch, M. S. et al. (1998). Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. New England Journal of Medicine 339 1261-8.
57. Martinez-Picado, J., DePasquale, M. P., Kartsonis, N. et al. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academic of Sciences USA 97, 10948-53.